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ABSTRACT 
The aim of this study was to determine whether wrist actigraphy could be used to assess the 
daytime effects of stimulant medication treatment in narcolepsy. Nine subjects with 
narcolepsy/cataplexy (medicated and unmedicated) were compared with matched control subjects. 
Data was collected over four days in the subjects' home. It was found that the actigraph variable of 
Immobility (mean duration of periods of no activity) could be used to successfully differentiate 
medicated and unmedicated phases, correctly classifying 89% of cases. Narcolepsy subjects 
differed from controls on Immobility both when medicated and unmedicated. During the 
unmedicated phase self-reported nap duration was longer and more naps (3.94 naps) were taken. 
However, the frequency of naps was still high when medicated (2.43 naps). During the unmedicated 
phase narcolepsy subjects reported more negative mood states (Profile of Mood States, POMS) than 
control subjects. However, with the exception of Vigor, scores on the individual mood factors were 
within the normal range. Total POMS scores were highly correlated with the actigraphic measure of 
Movement for both narcolepsy conditions as well as controls, with negative mood associated with 
less movement. It was concluded that the actigraphy variable of Immobility is sensitive enough to 
detect treatment effects. The relationship between mood and motor activity warrants further 
investigation in both clinical and non-clinical populations. 
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INTRODUCTION 
In the absence of an objective, reliable, ecologically valid and cost effective method of quantifying 
the effects of stimulant medication on daytime functioning in narcolepsy, clinicians have relied 
heavily on individual patient's reports. Self-reports of sleepiness and diurnal function are currently 
the main parameters used to estimate of treatment effectiveness in clinical setting. However, 
individuals with narcolepsy often underestimate daytime sleep (Rogers et al., 1994) and have been 
hypothesised to lack an appropriate frame of reference for evaluating treatment efficacy (Mitler et 
al., 1993). In a study of 522 patients with narcolepsy (Sangal et al., 1999), estimates of sleep 
propensity [Epworth Sleepiness Scale, ESS; Johns, 1991)] were shown to remain unchanged despite 
objectively measured changes in sleep propensity in the laboratory (Maintenance of Wakefulness 
Test, MWT). Costly sleep laboratory based procedures such as the Multiple Sleep Latency Test 
(MSLT) and MWT provide inconsistent results in the evaluation of treatment efficacy of disorders 
of excessive sleepiness (Mitler et al., 1982, 1990, 1991, 1993). In addition, external validity is 
questionable due to confounding motivational and environmental factors inherent under laboratory 
conditions (Broughton et al., 1988; Roth et al., 1994). Thus, clinicians may not know how much to 
trust the patient's subjective perceptions of treatment efficacy or be guided by the objective 
laboratory procedures that may not necessarily reflect a patient's usual sleep propensity.  
 
The American Sleep Disorders Association (ASDA, 1992) recommended that wrist actigraphy, 
being home-based, may be useful in conjunction with other measures to document the severity of 
sleep disorders. Similarly, others researchers (Stanley 2003, Sadeh 1995) have suggested that 
actigraphy is a potentially useful and cost-effective data collection tool that may be used to explore 
sleep-wake activity, monitor treatment processes and activity rhythms. To date, only a single study 
by Hajek et al.(1989) has used actigraphy to assess treatment effects in narcolepsy patients. This 
study found that a small group of narcolepsy subjects exposed to bright light showed no 
improvement in either objectively or subjectively measured symptoms. 
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Middelkoop et al. (1995) investigated the circadian distribution of activity in unmedicated 
narcolepsy and matched control subjects and found that during the day the actigraph variable of 
"mean duration of uninterrupted immobility" (hereafter called Immobility), successfully 
discriminated between narcolepsy and control subjects. It was concluded that higher Immobility 
values were most likely caused by intermittent episodes of sleep during the major wake period. 
However, the other variables of mean diurnal Activity level and Movement index did not differ 
significantly between experimental and control groups. 
 
The main aim of this study was to determine whether wrist actigraphy variables may be useful in 
the assessment of the effects of stimulant medication treatment in narcolepsy. Therefore, motor 
activity measures related to daytime behaviour were compared in medicated and unmedicated 
narcolepsy subjects. Data from age- and sex- matched control subjects were also collected to (1) 
confirm Middelkoop et al.’s (1995) finding that actigraphy can discriminate between the daytime 
activity of narcolepsy and control subjects; and (2) determine to what extent stimulant medication 
brings measures of daytime function measures closer to levels reported by individuals without 
pathological sleepiness. Self-report measures of mood and sleep-wake behaviour were also 
collected in order to (1) determine possible subjective differences due to treatment; (2) compare 
self-report variables with actigraphy variables; and (3) investigate differences between 
unmedicated, medicated and control subjects. Data were collected over consecutive days and nights, 
but only the finding for diurnal behaviour are discussed here. The nocturnal data will be the subject 
of a subsequent paper.  
 
METHOD 
Subjects 
Subjects in the narcolepsy group were six females (aged from 41 to 70, mean age = 57.3, SD = 9.9) 
and three males (aged 19 to 63, mean age = 39.6, SD = 22.1). The control subjects were age- and 
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sex- matched as closely as possible (within three years) to the narcolepsy subjects and consisted of 
six females (aged 42 to 71, mean age = 56.1, SD = 8.9) and three males (aged 19 to 65 years, mean 
= 41.0, SD = 23.1). All subjects in the narcolepsy group had previously been diagnosed by a 
medical specialist and displayed unambiguous cataplexy. Two subjects with narcolepsy were also 
being treated for sleep apnoea with Continuous Positive Airway Pressure (CPAP). During the 
unmedicated phase of the study, narcolepsy subjects were required to withdraw from all stimulant 
medication for a period of 60 hours before the first evening recording period. Thus, when the 
diurnal actigraphy commenced, the narcoleptic subjects had gone without stimulant medication for 
about 72 hours.  Many people with narcolepsy report taking drug holidays when circumstances 
permit. Therefore, the drug-free period required in this study would not have necessarily been 
unusual for the subjects.  Both the stimulants used by the patients have a relatively short half-life 
(10-12 hours for dexamphetamine and 2-3 hours for methylphenidate) and it is likely that at least 
90% would have been excreted from the body within the pre-testing withdrawal phase.  Parkes and 
Dahlitz (1993) suggest that the main rebound sleepiness lasts 2-3 days.  While a longer withdrawal 
period would have been more desirable, the pool of potential subjects would have been smaller and 
compliance probably much less likely. Compliance with treatment withdrawal was confirmed at the 
beginning and end of the study period by the analysis of urine samples collected in the Victoria 
University Sleep Laboratory. Urine samples were subsequently analysed for stimulant medication 
metabolites by Australian Research Laboratories in Melbourne, Australia. These analyses showed 
that all subjects remained free of stimulant medication during the untreated phases of the study. All 
other regular medications were maintained during the study and no subjects were taking 
tranquillisers. During the medicated phase, all narcolepsy subjects took their normal daily dose of 
stimulant medication (Ritalin or Dexamphetamine). All day periods were spent in the subject's own 
home environment, while the narcolepsy subjects (but not the controls) slept in the Sleep 
Laboratory on Nights One and Four and left after breakfast. The narcolepsy subjects were recruited 
through local members of the Australian narcolepsy support group, (Narcolepsy and Overwhelming 
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Daytime Sleep Society, NODSS). The control subjects were all acquaintances of the authors and 
were all normal sleepers with no diagnosed chronic and/or serious medical conditions. Control and 
narcolepsy subjects were paid $60 to cover any expenses incurred while participating in the study. 
Actigraphy  
Motor activity was continuously recorded using a Mini-Mitter 2000 Mini Logger wrist actigraph 
(Mini-Mitter Co., Inc., USA), worn on the nondominant arm, from the evening of Day One to the 
morning after Night Four (Middlekoop et al. (1995) used Gaehwiler Electronic wrist actigraphs, 
model CH-8634, Hombrechtikon, GDR). The accelerometer sensitivity of  the Gaehwiler Electronic 
wrist actigraph used by Middelkoop et al., (1995) was > 0.1g and that of the Mini-Mitter used in 
this study was > 0.05g). Three complete day periods were obtained (Days Two, Three and Four), 
sufficient to obtain a representative description of sleep-wake behaviour in narcolepsy (ASDA, 
1992: Middelkoop et al 1995). Movements were recorded in 16-second bins. The motor activity 
measures reported by Middelkoop et al.(1995) were adapted and calculated across each selected 
period: [a] Activity = mean number of activity counts per 16 second epoch;  [b] Movement = the 
percentage of epochs with an activity count  > 0 across the entire period; and  [c] Immobility = the 
mean duration in minutes of uninterrupted immobility (that is where activity = 0).  Each diurnal 
period was selected using the Sleep Diary (see below) reports from "time finally awoke" to "time 
tried to go to sleep" for the main night's sleep. The actigraphy variables were computed from the 
raw data using software (NEWVUT). The NEWVUT software was designed to calculate the 
actigraph variables in the manner described by Middelkoop et al. (1995). 
Questionnaires 
During the day/evening each subject completed the following questionnaires: [a] Profile of Mood 
States (POMS)- a checklist of 65 items related to mood developed by McNair et al. (1981). Each 
item is rated on a 5-point Likert scale and the POMS Total score consists of the sum of scores from 
the negative subscales- Confusion/Bewilderment, Anger/Hostility, Tension/Anxiety, Fatigue and 
Depression. The positive subscale, Vigour, is not included in the total score. POMS ratings related 
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to the day just completed; [b] Epworth Sleepiness Scale (ESS) a measure of sleep propensity in a 
variety of situations with a score range from 0 to 24. This was adapted to relate to the day just 
completed rather than "in recent times"; [c] a Day Log to record daytime naps, medication, caffeine 
or alcohol intake and times of removal of the wrist actigraph (e.g. for showering); and [d] a Sleep 
Diary completed each morning by the subjects. The beginning and end points for each diurnal (i.e 
wake) period of actigraphy were extracted from the diary. 
Procedure  
The narcolepsy subjects participated in two phases, unmedicated and medicated. Each phase 
consisted of a continuous four-day and four night period. The unmedicated phase was always 
conducted first (to reduce subject attrition). The procedures used in the study were approved by the 
Victoria University Human Experimentation Ethics Committee and informed consent was obtained 
from each subject. Urine samples were obtained on Nights One and Four, when the subjects 
attended the Sleep Laboratory. During the medicated phase subjects were requested to maintain 
their usual stimulant medication intake levels. If the usual level varied significantly from day to 
day, subjects were requested take their usual dose prescribed for maximum alertness. Subjects were 
instructed to maintain their normal 24-hour schedule (the sleep periods in the sleep laboratory were 
scheduled to fit with this) and engage in their normal daytime activities, but to moderate caffeine 
and alcohol intake. The scheduling of experimental days controlled for the possibility of different 
levels of activity on weekdays or weekends.  For the narcolepsy subjects participation was either all 
on weekdays in both medicated or unmedicated phases, or included a weekend in both phases.  
Control subjects were yoked to the same schedule as matched narcolepsy subjects, thus including 
either weekend or weekdays. 
Data Analysis 
The times when the actigraph were not worn were extracted from the Day Log and these data were 
eliminated prior to data analysis. Given that the three groups (unmedicated narcolepsy, medicated 
narcolepsy and controls) were either individuals undergoing repeated testing or carefully matched 
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controls, repeated measures statistics were used. The main analysis was a MANOVA with repeated 
measures, conducted across the three groups, using five dependent variables as described below. In 
the event of an overall MANOVA being significant, univariate effects for dependent variables were 
explored. Where these were significant, planned contrasts were used to determine the nature of the 
between groups effects for the relevant variables. A significance level of 0.05 was set. 
 
The dependent variables analysed were the actigraph variables of Activity, Movement and 
Immobility and the self-report variables of ESS, POMS Total, Nap Duration and Number of Naps. 
The control subject’s data for both Nap Duration and Number of Naps did not meet the normal 
distribution assumption required for MANOVA (control nap data was zero), and therefore these 
variables were not included in the MANOVA comparing the medicated and unmedicated subjects 
and the control group.  However, these data were analysed separately using paired sample t-Tests 
comparing only the medicated and unmedicated groups. 
 
A stepwise discriminant function analysis using SPSS (2000, Version 10.0) default settings was 
conducted to determine which of the dependent variables (using all seven as described above) best 
discriminated between the medicated and unmedicated groups. The "leave-one-out" classification 
method was used. A second discriminant analysis considered only the four self-report variables. 
 
Where a planned contrast showed a significant difference for POMS Total scores between 
medicated and unmedicated narcolepsy and control subjects, possible differences on each of the six 
POMS factors were also examined investigated using paired sample t-Tests. 
 
In order the determine whether there was any relationship between the objective actigraph variables 
and the subjective self-report variables for the medicated and unmedicated narcolepsy and the 
control subjects a series of bivariate Pearson's correlations were calculated.  
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RESULTS 
For the self-report variables, four diurnal periods were available (Days One to Four), while 
actigraphy data from three diurnal periods (Day Two to Four) were collected. MANOVA tests for 
the main effect of days were all non-significant within each group, so mean values for each variable 
across all the days available were calculated and used in the analyses. Using MANOVA, the five 
dependent variables as described above (three actigraph and two self-report variables) were 
compared. A significant overall group effect was found  (F (2,6)= 14.78, p=0.005). Planned 
contrasts were conducted between: (1) medicated and unmedicated narcolepsy phases; (2) control 
subjects and medicated narcolepsy subjects; and (3) control subjects and unmedicated narcolepsy 
subjects (Table 1). 
 
Actigraphy 
Table 1 shows that differences were found between the medicated and unmedicated narcolepsy 
subjects, and both medicated and unmedicated narcolepsy and control subjects for the actigraph 
variable of  Immobility.  Narcolepsy subjects, (particularly unmedicated) showed significantly 
longer periods of Immobility. The data for the individual narcolepsy subjects are shown in Figure 1. 
These data indicate that all narcolepsy subjects had much higher Immobility values when 
unmedicated compared to when taking stimulant medication. There were no significant differences 
between the narcolepsy and control groups with respect to the other two actigraph variables that 
measured overall activity level (Activity) and percentage of time during the diurnal period spent 
moving (Movement). Inspection of the direction of differences across individual case data for 
Activity and Movement indicated that there was no apparent consistency. 
Table 1. Means, Standard Deviations, Univariate and Planned Contrast Results for Unmedicated and Medicated Narcolepsy and Matched Control Subjects. 
 
 
 Unmed Narcolepsy  
(n=9) 
Control Subjects 
(n=9) 
Med Narcolepsy  
(n=9) 
Univariate Results Unmed Narcolepsy  
vs. Med  Narcolepsy
Unmed  Narcolepsy  
vs. Control 
Med Narcolepsy  
vs. Control 
 Mean 
 
SD Mean  SD Mean SD F p Planned contrast/ t-
test (see text) p 
Planned contrast p Planned contrast p 
Activity 
 
 
3.54 (1.77) 4.23 (4.79) 4.49 (2.19) 1.66 ns ns ns ns 
Movement 
 
 
42.51 (10.33) 37.04 (22.29) 49.44 (13.57) 1.91 ns ns ns ns 
Immobility 
 
1.49 (0.94) 0.29 (0.04) 0.37 (0.072) 15.81 0.0001 .006 0.005 0.03 
 
POMS total 
 
29.55 20.9 -6.66 17.34 21.09 35.93 5.18 0.021 ns 0.001 0.056 
Epworth 
Sleepiness 
Scale 
 
18.43 (4.36) 5.12 (2.16) 15.12 (5.83) 21.42 0.0001 ns 0.0001 0.005 
Number of 
Naps 
3.94 (1.33) 00 (00) 2.43 (1.38)   0.048    
Nap 
Duration 
 
 
 
 
73.54 (23.37) 0 (00) 34.79 (33.43)   .056   
 
  
0
1
2
3
4
5
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Figure 1.   Comparison of Actigraph Immobility Scores of Individual Narcoleptics (when 
Unmedicated and Medicated) with Matched Control Subjects.
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Treatment Effects And Discriminant Analysis 
In order to focus specifically on treatment effects, all seven dependent variables were submitted to a 
step-wise discriminant analysis performed between medicated and unmedicated narcolepsy 
subjects.  The only variable to enter the analysis was the actigraph variable of Immobility and this 
variable accounted for 42% of the total between treatment variance (Wilks lambda=0.579, p=0.005; 
Eigen value =0.728). The Immobility variable correctly classified 89% of cases into medicated or 
unmedicated narcolepsy (8/9), with 77.8% of medicated cases and 100% of unmedicated cases 
correctly classified. 
 
To facilitate comparisons with the above, a second discriminant analysis was performed between 
medicated and unmedicated narcolepsy using only the four self-report variables (ESS, POMS total, 
Nap Duration and Nap Number). Nap Duration was the only variable to enter the analysis, 
accounting for 31% of the total explained between treatment variance (Wilks lambda =0.687, 
p=0.02; Eigen value =0.455) and correctly classified 66.7% of cases (6/9 in both medicated and 
unmedicated narcolepsy subjects). 
Self-Report Variables 
Details of mean values and results of analyses for these variables are shown in Table 1. The control 
group did not report any napping and medicated narcolepsy subjects spent less time napping than 
unmedicated subjects with narcolepsy.  The mean number of reported naps differed significantly 
between medicated and unmedicated narcolepsy.  Seven of the nine narcolepsy subjects had less 
naps when on medication, one the same number and one more naps when medicated. Dividing 
mean Nap Duration values by the mean Number of Naps showed that medicated narcolepsy 
subjetcs had fewer naps and that, on average, naps were four minutes shorter than naps in the 
unmedicated condition. 
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Significant differences were found between the control group and both the medicated and 
unmedicated narcolepsy treatments for ESS scores.  However, there was no difference between ESS 
scores for medicated and unmedicated treatments.   
 
There was significant difference between the unmedicated narcolepsy and control subjects, and a 
trend for medicated narcolepsy subjects to differ from control subjects on the POMS Total scores. 
Given the significant difference between unmedicated narcolepsy subjects and control subjects for 
POMS Total scores a more detailed exploration was carried out to determine which of the 
individual POMS factors contributed to this difference. Means, standard deviations and paired 
samples t-Test results for control versus unmedicated narcolepsy subjects for the POMS factors are 
shown in Table 2. Table 2 shows that unmedicated narcolepsy subjects reported significantly more 
confusion, fatigue, depression, tension and less vigor than control subjects.   
Table 2. Means and Standard Deviations for the POMS Factors for Unmedicated and Medicated 
Narcolepsy  and Matched Control Subject Groups and Paired Sample t-Test Comparisons between 
Unmedicated Narcolepsy  and Matched Control Subjects. 
 
 
POMS Factors Unmed 
Narcolepsy s 
(n=9) 
Control 
Subjects 
(n=9) 
Med Narcolepsy 
s 
(n=9) 
Unmed Narcolepsy  
vs. Control Subjects 
(df=8) 
 Mean 
 
SD Mean  SD Mean SD  t  p 
Confusion/ 
Bewilderment 
 
8.64 4.92 2.42 2.09 7.03 5.36 3.27 0.011 
Vigour 
 
8.00 7.09 17.75 8.80 13.12 6.60 2.68 0.028 
Fatigue 
 
15.19 8.90 3.41 3.80 9.60 7.84 3.07 0.015 
Depression/ 
Dejection 
 
5.00 4.07 1.19 1.81 6.79 10.79 2.42 0.042 
Tension/Anxiety 
 
4.86 2.44 2.47 1.89 5.61 4.47 2.75 0.025 
Anger/Hostility 
 
3.86 5.25 1.58 2.42 5.33 6.26 1.15 ns 
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Correlations For Self-Report and Actigraphy Variables 
For the medicated and unmedicated narcolepsy and control subjects correlations between the three 
actigraph and four self-report variables were calculated (Table 3). It was found that the POMS Total 
score correlated with Movement for medicated and unmedicated narcolepsy subjects and control 
subjects with a significance level greater than p = 0.03 (Table 3).  Significant correlations were also 
found between POMS Total and Immobility for unmedicated narcolepsy and between POMS Total 
and Activity for control subjects. Scatterplots confirmed the fundamental linearity of the 
relationships. Correlations showed that increased Movement/Activity was associated with a more 
negative mood (higher POMS Total). In order to explore whether there were particular mood 
factors contributing to these correlations, further correlations were calculated between Movement 
and the six individual POMS factors for all three groups. For medicated narcolepsy subjects the 
factors tension, depression, anger and fatigue correlated with Movement in descending order of 
magnitude (from r=-0.86, p=0.003 to r=-0.69, p=0.038). For control subjects Movement was 
correlated with anger, depression and vigour (from –0.76, p= 0.018 to 0.669, p=0.049). There were 
no significant correlations between Movement and individual POMS factors in the unmedicated 
condition. 
Table 3.  Pearson Correlation Coefficients for the POMS Total Scores with the Three Actigraphy 
Variables Scores for Unmedicated and Medicated Narcolepsy and Matched Control Subjects. 
 
 
 
 
Unmed N 
(n=9) 
 Med N 
(n=9) 
 Control 
(n=9) 
 
   r 
 
p  r p   r p 
Activity 
 
-0.51 ns -0.57 ns -0.69 0.03 
Movement 
 
-0.77 0.01 -0.85 0.004 -0.71 0.02 
Immobility 
 
 0.71 0.03  0.59 ns  0.13 ns 
 
 
DISCUSSION 
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The finding of the present study showed that actigraphy is a useful tool for examining diurnal 
stimulant medication treatment effects in narcolepsy when the dependent variable Immobility is 
used.  Planned contrast tests yielded highly significant differences on the Immobility variable 
(Table 1)  with all nine narcolepsy subjects showing differences in the expected direction (Figure 
1). Immobility was the only variable that entered the discriminant analysis and was able to correctly 
classify 89% of cases as medicated or unmedicated. This compared favourably to the self-report 
variables, where Nap Duration only classified 66.7% of cases as medicated or unmedicated. 
 
The trend for differences in the Nap Duration between medicated and unmedicated narcolepsy 
treatments and the significant difference in number of reported naps may be contributing to the 
difference in Immobility. Webster et al. (1982) believed actigraph Immobility predominantly 
reflected features of sleep-wake behaviour.  Similarly, Middelkoop et al. (1995) attributed higher 
diurnal Immobility values in narcolepsy to intermittent episodes of sleep during the major wake 
period. However, it is not clear whether the Immobility differences can be fully accounted for by 
differences in reported nap behaviour or whether unmedicated narcolepsy subjects may be unaware 
of having more intermittent short episodes of sleep (Mitler et al., 1982). The fact that the other 
actigraphy variables, Activity and Movement, did not differ between medicated and unmedicated 
treatments suggests that the lack of medication does not lead to an overall significant reduction in 
activity level. Similarly, Middelkoop et al. (1995) found no differences in these two actigraphic 
variables between unmedicated narcolepsy and control groups during the day. This may arise 
because people with narcolepsy maintain a higher motor activity level than controls between 
immobile periods. Perhaps they stay "on the go" more to help maintain arousal.   
 
While medication brought the treated narcolepsy subjects closer to control subjects’ values of 
Immobility, a difference was still apparent. This confirms findings from other studies using 
different evaluation methods, such as the Maintenance of Wakefulness Test (Mitler et al., 1992) and 
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home polysomnographic recorders (Rogers et al., 1994), that stimulant medication improves 
daytime sleepiness in narcolepsy but not to levels that are non-pathological. In the current study, 
during the medicated phase subjects still slept an average of 34.8 minutes during the day and had 
2.43 naps. These findings are comparable with those of Rogers et al. (1994) where 25 medicated 
narcolepsy patients averaged somewhat more daytime sleep (43 minutes) but did so with less naps 
(1.6). The differences found between narcolepsy and control subjects were also consistent with the 
findings of Middelkoop et al. (1995) who found that the measure of actigraphic Immobility was the 
most sensitive discriminator between unmedicated narcolepsy and control subjects in both diurnal 
and nocturnal sleep periods.  
 
The control subjects scores on the ESS for sleep propensity showed differences from both 
medicated and unmedicated treatments. Mean values reported by control subjects and unmedicated 
narcolepsy subjects were similar to those reported previously (Johns 1991). Comparing medicated 
and unmedicated narcolepsy ESS scores from the current study to those reported by Parkes (1994), 
shows that medicated narcolepsy subjects had comparable values, but that unmedicated narcolepsy 
people had higher ESS values in Parkes study (20.2 versus 18.4 in present study). This finding 
provides some tentative support for the contention that any rebound sleepiness effect from stimulant 
medication withdrawal during this study would be minimal.  This contention is also supported by 
the lack of a significant difference in sleepiness in the unmedicated narcolepsy group from the first 
to the third day of actigraphy recording. 
 
There was no difference found between medicated and unmedicated narcolepsy for POMS Total 
scores (Table 1). However, the mean values suggested that further exploration with a larger sample 
may be warranted.  With a larger sample it would be interesting to compare scores assessing mood 
on and off medication over a period of several days with the findings of Zwicker et al. (1995) where 
acute mood improvement over a 90-minute period was found with stimulant intake in 40 narcolepsy 
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subjects. With respect to individual mood factors it would be of particular interest to explore 
changes in depressed mood. As the current study (involving the mean of four daily ratings) suggests 
highly variable depression ratings when comparing medicated and unmedicated phases (assessed 
via inspection of individual data and the large standard deviations). While the Zwicker et al. study 
examined acute effects, the current study rating period covered four whole day periods where 
subjects experienced both the active, acute therapeutic effects of stimulants and the period where 
the stimulants were wearing off (reported to be associated with negative affect in some patients).   
 
 The findings with respect to the individual POMS factors (Table 2) suggest that compared to 
control subjects, unmedicated people with narcolepsy are more confused, fatigued, tense, depressed 
and have less vigour. However, some caution needs to be used in interpreting this data. Comparison 
of the unmedicated narcolepsy subjects’ mean POMS scores with norms for college populations 
and outpatients (with no psychiatric disorder) (POMS Manual) (McNair et al. 1981) shows that all 
unmedicated narcolepsy scores were within one standard deviation of the normative group means, 
except for Vigour which was below this range.  
 
While actigraphy measures have been shown not to correlate with subjective Sleep Diary reports in 
narcolepsy (Middelkoop et al., 1995), the association between actigraph variables and mood in 
narcolepsy has not previously been explored. Strong negative correlations were found between the 
POMS Total score and the actigraphy variable of Movement in medicated and unmedicated 
narcolepsy and control subjects. Narcolepsy and control subjects who reported more negative affect 
showed a lower percentage of movement epochs across the day. Interestingly, the correlations 
between the actigraphy variable and mood occurred in the absence of correlation of the actigraphy 
variable with sleep propensity estimates (ESS), Nap Duration, or Number of Naps. Given the small 
sample size, over interpretation of the particular POMS factors contributing to the strong 
association with Movement should be avoided. However, these preliminary data suggest that the 
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mood factors of tension, depression and anger may be strongly associated with Movement in the 
clinical and control populations. Low levels of daytime activity, measured with actigraphy, has 
been related to the severity of depression in psychiatric (Teicher 1995) and non-psychiatric 
depressed patients (Mendlowicz et al.1999). Consistent with this, treatment effects of 
antidepressants have been successfully monitored in major depressive disorder using diurnal 
actigraphy (Volkers et al., 2002). The findings of a negative association between movement and 
mood in both narcolepsy and control groups suggests that it may be useful to include the POMS 
questionnaire in studies involving actigraphy in a variety of other clinical and non-clinical 
populations. 
 
The actigraphic study of nocturnal sleep has seen the development of many different algorithms 
with various degrees of correlation with polysomnographic measures (Hajek et al., 1989). The study 
of diurnal functioning using actigraphs has had to adopt different measures. Given the current 
results, together with those found by Middelkoop et al. (1995), it would be potentially valuable for 
all daytime actigraphic studies to include an analysis of the mean duration of Immobility as a 
dependent variable.   
 
Comparison of the current mean scores for Activity and Movement with the values obtained in a 
study using similar populations but a different brand of actigraph (Middelkoop et al., 1995) shows 
quite different values.  However, the scores for the Immobility variable are comparable across the 
two studies. Thus, both would appear to have similar movement detection thresholds. Useful 
comparisons of Immobility scores across studies would be possible if the same threshold for 
activity movement detection was adopted internationally. 
 
The use of actigraphy in the clinical assessment of both sleep disorders and psychopharmacology is 
becoming widespread, with a growing literature of review papers, validation studies and practice 
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parameters (ASDA 1992; Sadeh et al.,1995, Ancoli-Israel et al., 2003, Littner et al., 2003, de Souza 
et al., 2003, Stanley 2003). The current study suggests that actigraphy may have a useful role in 
assessing treatment effects in narcolepsy and that further research is required to determine how 
robust the Immobility measure is in a variety of clinical settings. This could include further short-
term and longitudinal study of pharmacological and behavioural treatment efficacy as well as 
further study of the association between actigraphy and subjective reports of mood. 
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